ASP Isotopes supports IsoBio with Series Seed; webcast on July 30, 2025

Rhea-AI Filing Summary

ASP Isotopes Inc. (Nasdaq: ASPI) filed an 8-K dated 28 Jul 2025 to disclose a joint press release with IsoBio, Inc. announcing IsoBio’s initial Series Seed financing. The funds will be used to advance IsoBio’s proprietary Antibody-Isotope Conjugate platform (AICs TM) aimed at oncology indications.

The companies will host an investor webcast on 30 Jul 2025 at 10:00 a.m. ET to discuss the collaboration. No dollar amount, valuation or ownership details were provided in the filing. The press release is furnished as Exhibit 99.1 (excluding its fifth and sixth paragraphs). No other items, financial statements or pro-forma data accompanied the report.

For ASPI, the disclosure signals strategic expansion into radiopharma-enabled biologics but carries limited immediate financial visibility. The filing is informational and does not amend prior guidance or trigger accounting changes.

Insights

Life Sciences Analyst

TL;DR: ASPI funds IsoBio to develop AICs; strategic, but financial impact unclear.

The move positions ASPI’s isotope-enrichment expertise inside a dedicated biotech vehicle, potentially opening access to the fast-growing radiopharmaceutical oncology market. The webcast indicates active investor outreach, and seed funding de-risks early R&D. However, the absence of capital size, milestones or ownership terms prevents assessment of dilution, runway or value accretion. Near-term P&L effects are therefore indeterminate. Overall impact is strategically positive yet quantitatively opaque.

8-K Event Classification

2 items: 8.01, 9.01

2 items

Item 8.01 Other Events Other

Voluntary disclosure of events the company deems important to shareholders but not covered by other items.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

FAQ

What did ASP Isotopes (ASPI) announce in its 8-K dated July 28 2025?

The company reported IsoBio’s initial Series Seed funding to advance Antibody-Isotope Conjugates for cancer treatment and furnished the related press release as Exhibit 99.1.

When is the ASP Isotopes and IsoBio investor webcast?

The webcast is scheduled for Wednesday, July 30 2025 at 10:00 a.m. Eastern Time.

Which exhibit contains the press release about IsoBio’s seed funding?

The press release is provided as Exhibit 99.1 to the 8-K filing.

Does the 8-K disclose the size of IsoBio’s Series Seed round?

No. The filing does not specify the funding amount, valuation, or investor composition.

What new technology is highlighted in the press release?

IsoBio aims to develop Antibody-Isotope Conjugates (AICs TM), combining antibodies with isotopes for targeted cancer therapy.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Understanding 8-K Material Events →

Accepted by SEC EDGAR 07/28/2025 - 09:15 AM Learn about SEC filing dates

0001921865false00019218652025-07-282025-07-28iso4217:USDxbrli:sharesiso4217:USDxbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): July 28, 2025

ASP Isotopes Inc.

(Exact name of registrant as specified in its charter)

Delaware		001-41555		87-2618235
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification No.)

601 Pennsylvania Avenue NW South Building, Suite 900 Washington, DC		20004
(Address of principal executive offices)		(Zip Code)

Registrant’s telephone number, including area code: (202) 756-2245

Not Applicable

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading symbol(s)		Name of each exchange on which registered
Common Stock, par value $0.01		ASPI		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act ☐

Item 8.01. Other Events.

On July 28, 2025, ASP Isotopes Inc. and IsoBio, Inc. issued a press release announcing the initial Series Seed funding of IsoBio, Inc. to advance innovative Antibody-Isotope Conjugates (AICs^TM) for cancer treatment. ASP Isotopes Inc. and IsoBio, Inc. are hosting an investor webcast on Wednesday, July 30, 2025 at 10:00 AM Eastern to discuss the collaboration. A copy of the press release is attached to this Current Report on Form 8-K as Exhibit 99.1 and is incorporated herein by reference, other than the fifth and sixth paragraphs of the press release.

Item 9.01. Financial Statements and Exhibits.

Exhibit No.		Description
99.1		Press Release, dated July 28, 2025, of ASP Isotopes Inc. and IsoBio, Inc. announcing Series Seed funding of IsoBio, Inc. to advance innovative Antibody-Isotope Conjugates (AICsTM) for cancer treatment.
104		Cover Page Interactive Date File (embedded within the Inline XBRL document)

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	ASP ISOTOPES INC.
Date: July 28, 2025	By:	/s/ Paul Mann
	Name:	Paul Mann
	Title:	Chief Executive Officer

3